Select your Market

Global
Africa
Algeria
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Congo Democratic Republic
Djibouti
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Ivory Coast
Kenya
Lesotho
Liberia
Libya
Madagascar
Malawi
Mauritania
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria
Reunion Islands
Rwanda
Saint Helena
São Tomé and Príncipe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Asia
Bahrain
Bangladesh
China, mainland
India
Indonesia
Iran
Iraq
Israel
Japan
Jordan
Kuwait
Lebanon
Malaysia
Oman
Palestine
Philippines
Qatar
Saudi Arabia
Singapore
South Korea
Syria
Taiwan
Thailand
Turkey
United Arab Emirates
Vietnam
Yemen
Europe
Albania
Austria
Baltic Region
Belarus
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Netherlands
North Macedonia
Norway
Poland
Portugal
Romania
Russian Federation
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Türkiye
Ukraine
United Kingdom
Latin America
Argentina
Aruba
Bahamas
Barbados
Belize
Bolivia
Brazil
Central America
Chile
Colombia
Costa Rica
Cuba
Curacao-NL Antillen
Ecuador
El Salvador
Guatemala
Haiti
Honduras
Jamaica
Mexico
Nicaragua
Panama
Paraguay
Perú
República Dominicana
Trinidad and Tobago
Uruguay
Venezuela
North America
Canada
United States of America
Oceania
Australia
New Zealand
Global

Revolutionizing Drug Development

Faster drug discovery, reduced reliance on animal testing, and more reliable predictions of human organ responses. 

Microphysiological Systems (MPS) are pioneering innovative in vitro platforms that replicate human organ responses, ultimately enhancing drug development and reducing reliance on animal testing. By mimicking human organ-level functions on a microfluidic platform, MPS enables more predictive, mechanism-driven insights for drug discovery, safety, and disease research. 

Our Objectives

To Enhance Drug Testing Efficiency:

  • Develop MPS models to accelerate drug testing by accurately simulating human responses, reducing the time and cost of bringing new therapies to market.

To Improve Predictive Accuracy:

  • Utilize MPS to enhance the reliability of preclinical results, ensuring better translatability of research to clinical outcomes by mimicking complex organ interactions.

To Reduce Reliance on Animal Testing:

  • Minimize animal use in research by providing ethical alternatives through MPS, supporting the principles of the 4Rs (Replacement, Reduction, Refinement and Responsibility).

Key Features

Integrated Sensors:

  • Utilizing advanced semiconductor integration, researchers will be able to collect time relevant and high quality data.

Dynamic Microenvironment Control: 

  • Replicate physiological conditions through microfluidic systems that maintain cell viability and functionality, crucial for long-term studies. 

Integration of AI and Data Analytics:  

  • Leverage AI to analyze complex datasets, enhancing predictive modeling and decision-making in drug development. 

HUB Organoids

The acquisition of HUB Organoids Holding B.V. marks a significant advancement in our capabilities, allowing us to leverage their expertise in organoid technology. This integration enhances our MPS initiative, enabling more sophisticated and human-relevant testing methods. 

Explore organoid technology

Collaboration with imec

Strategic Partnership for Advanced MPS Development

Together with imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, we are developing an advanced Microphysiological Systems (MPS) platform. This collaboration aims to create next-generation MPS-on-a-chip through a multipartner program, enhancing drug discovery and expediting candidate development. By combining our life science expertise with imec’s cutting-edge semiconductor hardware, we aim to deliver unprecedented accuracy in simulating human body responses and generate high-quality training data for AI models, ultimately reducing reliance on animal testing. Learn more about imec.

Let’s Stay Connected

Join our ongoing conversations to develop the next generation of MPS models, with the potential to bring safer, more effective treatments to patients faster than ever before. Email us.